{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:11:28Z","timestamp":1786997488706,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.thromres.2024.02.018","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T06:16:25Z","timestamp":1708064185000},"page":"14-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Altered fibrin clot properties are associated with the progression of chronic kidney disease in atrial fibrillation"],"prefix":"10.1016","volume":"236","author":[{"given":"Zbigniew","family":"Heleniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142 T.","family":"Matusik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.thromres.2024.02.018_bb0005","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.018_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.018_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ehf2.13699","article-title":"Chronic kidney disease and risk of atrial fibrillation and heart failure in general population-based cohorts: the BiomarCaRE project","volume":"9","author":"Rehm","year":"2022","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.thromres.2024.02.018_bb0020","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.3390\/healthcare10122566","article-title":"Oral anticoagulation in patients with chronic kidney disease and non-Valvular atrial fibrillation: the FAERC study","volume":"10","author":"Montomoli","year":"2022","journal-title":"Healthcare"},{"issue":"6","key":"10.1016\/j.thromres.2024.02.018_bb0025","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ahj.2010.03.027","article-title":"Chronic kidney disease and prevalent atrial fibrillation: the chronic renal insufficiency cohort (CRIC)","volume":"159","author":"Soliman","year":"2010","journal-title":"Am. Heart J."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.018_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.006515","article-title":"Comparative effectiveness and safety of Oral anticoagulants across kidney function in patients with atrial fibrillation","volume":"13","author":"Yao","year":"2020","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.thromres.2024.02.018_bb0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ahj.2017.10.015","article-title":"Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time\u2014a RE-LY trial analysis","volume":"98","author":"Hijazi","year":"2018","journal-title":"Am. Heart J."},{"key":"10.1016\/j.thromres.2024.02.018_bb0040","article-title":"Effectiveness and safety of reduced dose non- vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted Nationwide cohort study","volume":"35","author":"Nielsen","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2024.02.018_bb0045","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2015.03.577","article-title":"Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial","volume":"65","author":"B\u00f6hm","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2024.02.018_bb0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.116.021890","article-title":"On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin","volume":"134","author":"Fordyce","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.thromres.2024.02.018_bb0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2024.02.018_bb0060","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2215\/CJN.02170218","article-title":"Clinical pharmacology of oral anticoagulants in patients with kidney disease","volume":"14","author":"Jain","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.thromres.2024.02.018_bb0065","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2021.33","article-title":"Management of heart failure in patients with chronic kidney disease","volume":"17","author":"Ryan","year":"2022","journal-title":"Eur. Cardiol."},{"key":"10.1016\/j.thromres.2024.02.018_bb0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0021-9150(97)00273-6","article-title":"Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease","volume":"137","author":"Irish","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2024.02.018_bb0075","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2215\/CJN.13121215","article-title":"Inflammation and progression of CKD: the CRIC study","volume":"11","author":"Amdur","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.018_bb0080","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.3390\/jcm9082476","article-title":"Chronic kidney disease and its impact on a prothrombotic state in patients with atrial fibrillation","volume":"9","author":"Matusik","year":"2020","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.018_bb0085","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.33963\/KP.a2021.0088","article-title":"Thromboembolism and bleeding in patients with atrial fibrillation and stage 4 chronic kidney disease: impact of biomarkers","volume":"79","author":"Matusik","year":"2021","journal-title":"Kardiol. Pol."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.018_bb0090","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/ndt\/gfm884","article-title":"Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality","volume":"23","author":"Undas","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.thromres.2024.02.018_bb0095","article-title":"Unfavorably altered fibrin clot properties are associated with recurrent venous thromboembolism in patients following post-discharge events","volume":"132","author":"Undas","year":"2022","journal-title":"Pol. Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.018_bb0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/cvr\/cvad017","article-title":"Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice","volume":"119","author":"Z\u0105bczyk","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.thromres.2024.02.018_bb0105","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3390\/biomedicines10092270","article-title":"Relationship between renal function, fibrin clot properties and lipoproteins in anticoagulated patients with atrial fibrillation","volume":"10","author":"Ding","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.thromres.2024.02.018_bb0110","article-title":"Fibrin clot properties in coronary artery disease: new determinants and prognostic markers","volume":"131","author":"Larsen","year":"2021","journal-title":"Pol. Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.018_bb0115","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00392-019-01522-x","article-title":"Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation","volume":"109","author":"Matusik","year":"2020","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.thromres.2024.02.018_bb0120","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.5603\/KP.2018.0134","article-title":"Association of cardiac troponin I with prothrombotic alterations in atrial fibrillation","volume":"76","author":"Matusik","year":"2018","journal-title":"Kardiol. Pol."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.018_bb0125","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.33963\/KP.a2021.0124","article-title":"Biomarkers for atrial fibrillation and chronic kidney disease: what is the evidence?","volume":"79","author":"Krittayaphong","year":"2021","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.thromres.2024.02.018_bb0130","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2147\/CIA.S138405","article-title":"R2(GFR)CHADS2 and R2(GFR)CHA2DS2VASc schemes improved the performance of CHADS2 and CHA2DS2VASc scores in death risk stratification of Chinese older patients with atrial fibrillation","volume":"12","author":"Fu","year":"2017","journal-title":"Clin. Interv. Aging"},{"issue":"6","key":"10.1016\/j.thromres.2024.02.018_bb0135","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/FJC.0000000000000911","article-title":"Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease stage G4: a single-center experience","volume":"76","author":"Heleniak","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.thromres.2024.02.018_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2022.07.034","article-title":"Elevated 8-isoprostane concentration is associated with thromboembolic events in patients with atrial fibrillation","volume":"365","author":"Mo\u0142ek","year":"2022","journal-title":"Int. J. Cardiol."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.018_bb0145","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2017-07-798306","article-title":"Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study","volume":"131","author":"Cieslik","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.02.018_bb0150","article-title":"Denser fibrin clot networks in patients at high risk of recurrent arterial thromboembolism following acute limb ischemia of unknown cause","volume":"132","author":"Nowakowski","year":"2022","journal-title":"Pol. Arch. Intern. Med."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.018_bb0155","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/aje\/kwm191","volume":"166","author":"Kaptoge","year":"2007","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.thromres.2024.02.018_bb0160","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/ki.2008.519","article-title":"Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4","volume":"111","author":"Goicoechea","year":"2008","journal-title":"Kidney Int. Suppl."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.018_bb0165","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ki.2011.214","article-title":"Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis","volume":"80","author":"Sorensen","year":"2011","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.018_bb0170","doi-asserted-by":"crossref","first-page":"F471","DOI":"10.1152\/ajprenal.00189.2014","article-title":"Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis","volume":"307","author":"Craciun","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"17","key":"10.1016\/j.thromres.2024.02.018_bb0175","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1523\/JNEUROSCI.0137-10.2010","article-title":"Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage","volume":"30","author":"Schachtrup","year":"2010","journal-title":"J. Neurosci."},{"issue":"13","key":"10.1016\/j.thromres.2024.02.018_bb0180","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gad.465908","article-title":"Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta\/alternative macrophage activation pathway","volume":"22","author":"Vidal","year":"2008","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.018_bb0185","first-page":"185","article-title":"Altered fibrin clot properties and fibrinolysis in patients with atrial fibrillation: practical implications","volume":"22","author":"Undas","year":"2020","journal-title":"Europace"},{"issue":"5","key":"10.1016\/j.thromres.2024.02.018_bb0190","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2022.07.026","article-title":"Arterial stiffness, endothelial dysfunction and impaired fibrinolysis are pathogenic mechanisms contributing to cardiovascular risk in ANCA-associated vasculitis","volume":"102","author":"Farrah","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.thromres.2024.02.018_bb0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-0036-1579636","article-title":"How to assess fibrinogen levels and fibrin clot properties in clinical practice?","volume":"42","author":"Undas","year":"2016","journal-title":"Semin. Thromb. Heamost."},{"key":"10.1016\/j.thromres.2024.02.018_bb0200","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MBC.0b013e32833a9035","article-title":"The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome","volume":"21","author":"Undas","year":"2010","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2024.02.018_bb0205","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.thromres.2020.10.039","article-title":"Observations on clot properties in atrial fibrillation: relation to renal function and choice of anticoagulant","volume":"197","author":"Khan","year":"2021","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.02.018_bb0210","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cjca.2019.01.014","article-title":"Prothrombotic State in Atrial Fibrillation Patients With One Additional Risk Factor of the CHA(2)DS(2)-VASc Score (Beyond Sex)","volume":"35","author":"G\u0142owicki","year":"2019","journal-title":"Can J. Cardiol."},{"key":"10.1016\/j.thromres.2024.02.018_bb0215","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/ATVBAHA.112.245308","article-title":"Antithrombin-independent effects of heparins on fibrin clot nanostructure","volume":"32","author":"Yeromonahos","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.018_bb0220","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-071907","article-title":"Oral anticoagulant switching in patients with atrial fibrillation: a scoping review","volume":"13","author":"Adelakun","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.thromres.2024.02.018_bb0225","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1053\/j.ajkd.2005.06.017","article-title":"B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy","volume":"46","author":"Vickery","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.thromres.2024.02.018_bb0230","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1093\/ndt\/gfs365","article-title":"Plasma B-type natriuretic peptide level predicts kidney prognosis in patients with predialysis chronic kidney disease","volume":"27","author":"Yasuda","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.018_bb0235","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1373\/clinchem.2019.305797","article-title":"Cardiac and stress biomarkers and chronic kidney disease progression: the CRIC study","volume":"65","author":"Bansal","year":"2019","journal-title":"Clin. Chem."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.018_bb0240","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000368915","article-title":"Association between chronic kidney disease progression and cardiovascular disease: results from the CRIC study","volume":"40","author":"Rahman","year":"2014","journal-title":"Am. J. Nephrol."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.018_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273646","article-title":"Association between atrial fibrillation and risk of end-stage renal disease among adults with diabetes mellitus","volume":"17","author":"Chang","year":"2022","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.thromres.2024.02.018_bb0250","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1160\/TH13-07-0566","article-title":"Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis","volume":"111","author":"Konieczy\u0144ska","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.02.018_bb0255","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/hrt.2010.192740","article-title":"Altered fibrin clot properties in patients with chronic heart failure and sinus rhythm: a novel prothrombotic mechanism","volume":"96","author":"Palka","year":"2010","journal-title":"Heart"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T10:18:46Z","timestamp":1717237126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824000537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":51,"alternative-id":["S0049384824000537"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.018","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered fibrin clot properties are associated with the progression of chronic kidney disease in atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}